vTv Therapeutics (VTVT) Notes Payables (2014 - 2025)

vTv Therapeutics has disclosed Notes Payables across 10 years of filings, most recently posting $328000.0 for Q3 2025.

• Notes Payables for Q3 2025 came in at $328000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $328000.0 (changed N/A YoY), and the FY2023 annual result was $191000.0, down 14.73% from the prior year.
• Notes Payables came in at $328000.0 for Q3 2025 at vTv Therapeutics, up from $191000.0 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $636000.0 in Q3 2021 to a low of $191000.0 in Q4 2023.
• The 4-year median for Notes Payables is $328000.0 (2025), against an average of $380714.3.
• Peak annual rise in Notes Payables reached 204.76% in 2021, while the deepest fall reached 73.15% in 2021.
• vTv Therapeutics' Notes Payables stood at $256000.0 in 2021, then declined by 12.5% to $224000.0 in 2022, then retreated by 14.73% to $191000.0 in 2023, then soared by 71.73% to $328000.0 in 2025.
• The last three Notes Payables figures came in at $328000.0 (Q3 2025), $191000.0 (Q4 2023), and $473000.0 (Q3 2023), per Business Quant data.